<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02056626</url>
  </required_header>
  <id_info>
    <org_study_id>5R01HL105520</org_study_id>
    <nct_id>NCT02056626</nct_id>
  </id_info>
  <brief_title>Conditioned Pharmacotherapeutic Effects in Hypertension</brief_title>
  <official_title>Conditioned Pharmacotherapeutic Effects in Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed research is designed to determine if the application of classical conditioning
      operations could influence the clinical effects of a regimen of antihypertensive drug
      therapy. It will be determined if, capitalizing on conditioned pharmacotherapeutic effects,
      patients can be effectively treated with smaller cumulative amounts of drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed research is designed to determine if the application of classical conditioning
      operations could influence the clinical effects of a regimen of antihypertensive drug
      therapy. In a double-blind, randomized, parallel-controlled clinical trial, It will be
      determined if, capitalizing on conditioned pharmacotherapeutic effects, patients can be
      effectively treated with smaller cumulative amounts of drug. To this end, some hypertensive
      patients will be treated on a partial rather than a continuous schedule of pharmacologic
      reinforcement. These patients will be compared to: (a) patients who continue to be treated
      under a standard regimen of pharmacotherapy at an effective dose of drug, and (b) patients
      who receive the same (reduced) cumulative amount of medication on a continuous schedule of
      reinforcement as that received by experimental patients treated under a partial schedule of
      reinforcement, and (c) patients who receive the same dose and frequency of carvedilol as the
      Partial Reinforcement Group but receive no intervening conditioned stimuli.

      It is possible that a non-continuous schedule of pharmacologic reinforcement (and the
      concomitant reduced amount of active drug) will exert effects that are indistinguishable from
      a continuous (standard) regimen of pharmacotherapy (a higher cumulative amount of drug). That
      outcome or comparison, however, is not critical for evaluating the role of conditioning in
      the pharmacotherapy of hypertension. Specifically, we will test the hypotheses that:

        1. patients treated under a partial schedule of antihypertensive medication will show a
           greater amelioration of symptoms than that achieved by patients treated with that same
           (reduced) amount of drug administered under a continuous schedule of reinforcement;

           Conditions permitting, we will also test the predictions that:

        2. irrespective of initial treatment regimen, relapse will occur more quickly following
           withdrawal of active medication in patients who do not continue to receive conditioned
           stimuli (placebo) than in patients who continue to receive conditioned stimuli; and

        3. when active drug is withdrawn and replaced by conditioned stimuli alone, resistance to
           extinction will be greater (i.e., rate of relapse will be less) among patients treated
           under a partial schedule of reinforcement than patients treated with the same amount of
           drug administered under a continuous schedule of reinforcement (the partial
           reinforcement effect).

      Positive results would transform the study and practice of pharmacotherapy with respect to
      placebo effects by providing a new model within which to design treatment protocols for
      patients with chronic diseases that capitalizes on conditioned pharmacotherapeutic responses.
      The model, from which testable hypotheses can be derived, also provides a new framework for
      research on placebo effects and the mechanisms underlying such phenomena.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">November 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Systolic Blood Pressure</measure>
    <time_frame>day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Systolic Blood Pressure</measure>
    <time_frame>day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Systolic Blood Pressure</measure>
    <time_frame>day 30</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>controlled dosing schedule 6.25 mg twice daily (15 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>controlled dosing schedule 6.25 mg twice daily, every other day (15 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard therapy, 25 mg twice daily (15 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carvedilol</intervention_name>
    <arm_group_label>arm 1</arm_group_label>
    <arm_group_label>arm 2</arm_group_label>
    <arm_group_label>arm 3</arm_group_label>
    <arm_group_label>arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  systolic blood pressure between 140-160 mmHG

          -  between 18-80 years old

        Exclusion Criteria:

          -  abnormal renal function

          -  currently pregnant, or trying to become pregnant

          -  being treated with a beta-blocker

          -  use of illicit drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John D. Bisognano, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>WOLF S. Effects of suggestion and conditioning on the action of chemical agents in human subjects; the pharmacology of placebos. J Clin Invest. 1950 Jan;29(1):100-9.</citation>
    <PMID>15399519</PMID>
  </reference>
  <reference>
    <citation>LASAGNA L, MOSTELLER F, VON FELSINGER JM, BEECHER HK. A study of the placebo response. Am J Med. 1954 Jun;16(6):770-9.</citation>
    <PMID>13158365</PMID>
  </reference>
  <reference>
    <citation>KNOWLES JB. CONDITIONING AND THE PLACEBO EFFECT: THE EFFECTS OF DECAFFEINATED COFFEE ON SIMPLE REACTION TIME IN HABITUAL COFFEE DRINKERS. Behav Res Ther. 1963 Aug;1:151-7.</citation>
    <PMID>14153340</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 4, 2014</study_first_submitted>
  <study_first_submitted_qc>February 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2014</study_first_posted>
  <results_first_submitted>May 23, 2019</results_first_submitted>
  <results_first_submitted_qc>May 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 13, 2019</results_first_posted>
  <last_update_submitted>June 26, 2019</last_update_submitted>
  <last_update_submitted_qc>June 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>John Bisognano</investigator_full_name>
    <investigator_title>M.D., Ph.D</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 3, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT02056626/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 26, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT02056626/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Partial Reinforcement</title>
          <description>partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)
carvedilol</description>
        </group>
        <group group_id="P2">
          <title>Controlled Dosing, Daily</title>
          <description>controlled dosing schedule 6.25 mg twice daily (15 days)
carvedilol</description>
        </group>
        <group group_id="P3">
          <title>Controlled Dosing, Every Other Day</title>
          <description>controlled dosing schedule 6.25 mg twice daily, every other day (15 days)
carvedilol</description>
        </group>
        <group group_id="P4">
          <title>Standard Therapy</title>
          <description>standard therapy, 25 mg twice daily (15 days)
carvedilol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>patient did not follow directions</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Partial Reinforcement</title>
          <description>partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)
carvedilol</description>
        </group>
        <group group_id="B2">
          <title>Controlled Dosing, Daily</title>
          <description>controlled dosing schedule 6.25 mg twice daily (15 days)
carvedilol</description>
        </group>
        <group group_id="B3">
          <title>Controlled Dosing, Every Other Day</title>
          <description>controlled dosing schedule 6.25 mg twice daily, every other day (15 days)
carvedilol</description>
        </group>
        <group group_id="B4">
          <title>Standard Therapy</title>
          <description>standard therapy, 25 mg twice daily (15 days)
carvedilol</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="14"/>
            <count group_id="B5" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.62" spread="10.23"/>
                    <measurement group_id="B2" value="52.62" spread="12.14"/>
                    <measurement group_id="B3" value="58.00" spread="6.88"/>
                    <measurement group_id="B4" value="56.21" spread="5.70"/>
                    <measurement group_id="B5" value="51.89" spread="10.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants taking other antihypertensives</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean systolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151.59" spread="7.22"/>
                    <measurement group_id="B2" value="152.64" spread="8.95"/>
                    <measurement group_id="B3" value="155.42" spread="9.62"/>
                    <measurement group_id="B4" value="151.88" spread="8.19"/>
                    <measurement group_id="B5" value="152.34" spread="8.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Systolic Blood Pressure</title>
        <time_frame>day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Partial Reinforcement</title>
            <description>partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)
carvedilol</description>
          </group>
          <group group_id="O2">
            <title>Controlled Dosing, Daily</title>
            <description>controlled dosing schedule 6.25 mg twice daily (15 days)
carvedilol</description>
          </group>
          <group group_id="O3">
            <title>Controlled Dosing, Every Other Day</title>
            <description>controlled dosing schedule 6.25 mg twice daily, every other day (15 days)
carvedilol</description>
          </group>
          <group group_id="O4">
            <title>Standard Therapy</title>
            <description>standard therapy, 25 mg twice daily (15 days)
carvedilol</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.59" spread="1.92"/>
                    <measurement group_id="O2" value="152.64" spread="2.38"/>
                    <measurement group_id="O3" value="155.42" spread="4.17"/>
                    <measurement group_id="O4" value="151.74" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Systolic Blood Pressure</title>
        <time_frame>day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Partial Reinforcement</title>
            <description>partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)
carvedilol</description>
          </group>
          <group group_id="O2">
            <title>Controlled Dosing, Daily</title>
            <description>controlled dosing schedule 6.25 mg twice daily (15 days)
carvedilol</description>
          </group>
          <group group_id="O3">
            <title>Controlled Dosing, Every Other Day</title>
            <description>controlled dosing schedule 6.25 mg twice daily, every other day (15 days)
carvedilol</description>
          </group>
          <group group_id="O4">
            <title>Standard Therapy</title>
            <description>standard therapy, 25 mg twice daily (15 days)
carvedilol</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.64" spread="2.58"/>
                    <measurement group_id="O2" value="132.92" spread="3.20"/>
                    <measurement group_id="O3" value="133.12" spread="3.20"/>
                    <measurement group_id="O4" value="135.00" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Systolic Blood Pressure</title>
        <time_frame>day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Partial Reinforcement</title>
            <description>partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)
carvedilol</description>
          </group>
          <group group_id="O2">
            <title>Controlled Dosing, Daily</title>
            <description>controlled dosing schedule 6.25 mg twice daily (15 days)
carvedilol</description>
          </group>
          <group group_id="O3">
            <title>Controlled Dosing, Every Other Day</title>
            <description>controlled dosing schedule 6.25 mg twice daily, every other day (15 days)
carvedilol</description>
          </group>
          <group group_id="O4">
            <title>Standard Therapy</title>
            <description>standard therapy, 25 mg twice daily (15 days)
carvedilol</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.90" spread="2.11"/>
                    <measurement group_id="O2" value="136.38" spread="3.34"/>
                    <measurement group_id="O3" value="139.27" spread="0.64"/>
                    <measurement group_id="O4" value="134.94" spread="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Partial Reinforcement</title>
          <description>partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)
carvedilol</description>
        </group>
        <group group_id="E2">
          <title>Controlled Dosing, Daily</title>
          <description>controlled dosing schedule 6.25 mg twice daily (15 days)
carvedilol</description>
        </group>
        <group group_id="E3">
          <title>Controlled Dosing, Every Other Day</title>
          <description>controlled dosing schedule 6.25 mg twice daily, every other day (15 days)
carvedilol</description>
        </group>
        <group group_id="E4">
          <title>Standard Therapy</title>
          <description>standard therapy, 25 mg twice daily (15 days)
carvedilol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was under enrolled and therefore not powered to answer the hypothesis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>John Bisognano</name_or_title>
      <organization>University of Rochester</organization>
      <phone>585-341-7800</phone>
      <email>john_bisognano @ urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

